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Abstract 
The first example of an octadentate gadolinium unit based on DO3A (hydration number q = 1) 
with a dithiocarbamate tether has been designed and attached to the surface of gold 
nanoparticles (around 4.4 nm in diameter). In addition to the superior robustness of this 
attachment, the restricted rotation of the Gd complex on the nanoparticle surface leads to a 
dramatic increase in relaxivity (r1) from 4.0 mM
-1 s-1 in unbound form to 34.3 mM-1 s-1 (at 10 
MHz, 37 °C) and 22 ± 2 mM-1s-1 (at 63.87 MHz, 25 °C) when immobilised on the surface. The 
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multifunctional gold nanoparticles. The incorporation of additional surface units improving 
biocompatibility (PEG and thioglucose units) and targeting (folic acid) lead to little detrimental 
effect on the high relaxivity observed for these non-toxic multifunctional materials. In addition 
to the passive targeting attributed to gold nanoparticles, the inclusion of a unit capable of 
targeting the folate receptors overexpressed by cancer cells, such as HeLa cells, illustrates the 





Partly due to its benign biological reputation, metallic gold has been used extensively in 
medicine to address applications such as imaging,1 therapy2 and drug delivery,3 including in 
clinical trials.4 Gold nanoparticles (GNPs) are amongst the most studied, partly due to the 
control which can be exerted over their dimensions and partly due to the straightforward 
attachment of molecules to the surface through sulfur linkages (principally thiols). The thermal 
response to near-IR light irradiation of gold nanostructures is routinely employed in 
photothermal therapy (PTT) to induce apoptotic cell death.5 Similar effects can also be 
achieved using photodynamic therapy (PDT), in which cytotoxic singlet oxygen / radicals are 
generated by the photoexcitation of suitable photosensitisers attached to the gold surface.6 
Furthermore, in vivo, even in the absence of functionalisation, gold nanoparticles accumulate 
at tumour sites (passive targeting) that have leaky, immature vasculature with wider 
fenestrations than normal mature blood vessels (enhanced permeability retention, EPR, 
effect).7 For these reasons, GNPs are increasingly being employed in cancer therapy.8 
In order to dramatically increase the selectivity of the targeting for certain cell types, 
additional surface units can be employed, such as aptamers (usually oligonucleotide or 
peptides) or antibodies.9 GNPs bearing these aptamers have been shown to result in very 
specific protein binding, and this has been used to bring the nanostructure into the proximity 
of target proteins expressed by certain cells.10 This targeting has been combined with 
photothermal therapy (PTT), in which irradiation of gold nanorods (GNR) leads to a 
temperature increase sufficient to cause destruction of the local environment.10  
Magnetic resonance imaging (MRI) is a medical imaging technique that exploits the 
same principles as nuclear magnetic resonance (NMR) to acquire (non-invasively) detailed 
anatomical images that display the highest spatial resolution of all the imaging modalities. 
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time, T1; transverse relaxation time, T2) and these parameters, in combination with proton 
density, govern contrast in MRI. This intrinsic contrast enables a detailed anatomical image to 
be acquired in MRI. Due to poor contrast between different tissue types (such as healthy and 
diseased), contrast agents can be used to accelerate the relaxation of local water protons in the 
surrounding tissue, improving the image detail. This can be achieved by the presence of an 
exogenous paramagnetic species, as T1 recovery and T2 decay are affected by the local magnetic 
moment. Higher relaxivity values (in mM-1 s-1) correlate with better contrast.11 Most contrast 
agents used in a clinical setting (such as Dotarem®, Figure 1a) are based on paramagnetic (4f7) 
trivalent gadolinium ions, which interact with water molecules to improve the relaxation rates 
of the protons, enhancing the image contrast.11 The attachment of Gd(III) units to the surface 
of gold nanoparticles has been shown previously to dramatically increase the relaxivity. This 
can be explained in terms of two parameters: Firstly, the rotational correlation time of the 
Gd(III) unit, which is greatly increased on binding to the nanoparticle surface. The nanoparticle 
assembly rotates more slowly than the unbound Gd(III) unit, leading to a rotational frequency 
closer in magnitude to the Larmor frequency and hence, enhanced relaxation rates.11 Secondly, 
the degree to which the relaxation of water protons changes is due to the multimeric effect 
which stems from the increased, localised contrast agent concentration.11,12,13 Many derivatives 
of DOTAREM have been used for this purpose, including DOTAGA, monoamido-DO3A 
(DOTMA) and DO3A.12c-e, 14 
 
To date, all clinically-approved gadolinium MRI contrast agents (e.g., Dotarem®, 
Figure 1a) are extracellular probes with a non-specific biodistribution. Hence, the work 
presented here forms part of the next generation of contrast agents, which are able to recognise 
specific molecules on the cellular surface of diseased cells that act as early reporters of a given 
pathology. The targeting of overexpressed membrane receptors using MRI is hampered by the 
very low concentration of such receptors and by the relatively low sensitivity of Gd(III) 
contrast agents. To overcome this limitation, the approach used here is to accumulate a large 
number of imaging reporters (hundreds of Gd chelates) at the target site through active 
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Figure 1. Design of a) clinically-approved contrast agent, Dotarem® (q = 1), b) hexacoordinate 
Gd chelate (q = 3) with a dithiocarbamate tether (shown in red), c) the octacoordinate Gd 
chelate (q = 1) with a dithiocarbamate tether reported in this work. 
 
Since 2008, we have focused on the functionalisation of gold nanoparticles (GNPs) 
with transition metal units.14-18 Much of this work has focused on the use of dithiocarbamate 
(R2NCS2) tethers rather than the usual thiol(ate) or disulfide attachment methodologies. 
Competition experiments by us19 and others20 have shown that dithiocarbamates are able to 
displace thiol(ate)s from the surface of the nanoparticle, but not vice versa. Surprisingly, this 
robust attachment approach has still not been embraced widely with only relatively few 
examples of metals being tethered to GNPs in this way.21 Theoretical investigations conducted 
using Au20 nanoclusters have provided an explanation for this more robust attachment.
22 They 
reveal much less distortion and reorganisation of the gold atoms compared to thiolates with no 
evidence of the ‘stapling’ effect observed structurally by Kornberg and co-workers in the 
crystal structure of Au102(SC6H4CO2H-4)44 nanoparticles (diameter 1.6 nm).
23 Stapling is the 
structural feature in which a gold atom is lifted out of the facet of gold atoms, potentially 
making it prone to loss as a molecular gold thiolate units.24 Though often unacknowledged, 
attachment through a single thiol(ate) tether can lead to detachment of some of the units from 
the nanoparticle surface under physiological conditions. It is well established that the 
performance of the contrast agent can be dramatically enhanced by increasing the mass of the 
assembly through attachment to polymers, liposomes, nanoparticles or multimetallic 
(metallostar) arrangements.11 This has been widely used in conjunction with various ways of 
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protons of the water molecules. In 2014, we reported for the first time how dithiocarbamates 
could be used to attach gadolinium units to GNPs for potential use in MRI contrast 
enhancement.15 These materials (Fig. 1b) showed promising relaxivity behaviour, however, the 
hexacoordinate coordination of the Gd3+ ion (q = 3) raised concerns over the potential loss of 
this toxic ion under physiological conditions and so this was a major factor in the new design 
described based on an octadentate coordination environment (Fig. 1c), found in Dotarem® (Fig. 
1a).25 
 
This approach uses the most robust tether (dithiocarbamate) to attach the most critical 
surface unit, the imaging modality. Thiol(ate)s can then be used as an orthogonal methodology 
to introduce additional groups, providing biocompatibility and targeting. The straightforward 
synthesis combined with the versatility offered by modular design, gives access to a wide range 
of materials that can be used as a platform for multimodal imaging. 
 
Results and discussion 
 
The new chelator 5 was prepared by a straightforward multi-step route (Scheme 1) starting 
from commercially-available cyclen via known intermediates 1·HBr, 2 and 3. All compounds, 
including previously unreported species (4 and 5), were fully characterized by 1H, 13C{1H} 
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Generation of the contrast agent was performed by addition of GdCl3·6H2O to 5 
(Scheme 2) followed by removal of any free (toxic) gadolinium ions (Xylenol orange test) as 
Gd(OH)3, precipitated under basic conditions. Infrared spectroscopic and mass spectrometry 




Scheme 2. Synthesis of 6 and the in situ conversion to dithiocarbamate-functionalised surface 
unit (7). 
 
Compound 6 was found to be stable for months as a solid and could be prepared and 
stored on a large scale (> 1 g). Addition of K2CO3 followed by carbon disulfide leads to the 
formation of the expected dithiocarbamate moiety (compound 7), in line with our previous 
studies on piperazine-based dithiocarbamate complexes.16,17,26 As discovered in these earlier 
studies, the long-term stability of 7, both in solution and in the solid state, was found to be 
significantly worse than that of 6, so compound 7 was always generated in situ when desired 
but not isolated. High-resolution mass spectrometry experiments nevertheless confirmed the 
generation of 7 (m/z 702.1025). Furthermore, solid state infrared absorptions measured for 7 
were attributed to ν(CN) and ν(CS) at 1396 cm-1 and 1002 cm-1, respectively, providing 
evidence for the formation of the dithiocarbamate. This was reinforced by a resonance at 212.0 
ppm in the 13C{1H} NMR spectrum obtained for the diamagnetic lanthanum (La3+, f0) analogue 
of 7, formed in an identical fashion. 
 
 Using a 0.25 T fast field cycling NMR relaxometer (see Supporting Information), the 
performance of 6 as an MRI contrast agent was established and compared to the current 
clinically-approved standard, Dotarem®. Compound 6 was found to possess a higher relaxivity 
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relaxivity.11 The Nuclear Magnetic Relaxation Dispersion (NMRD) profiles are shown in 
Figure 2. The presence of an amide arm on the chelates (as found in 6 and 7) has been reported 
to potentially impact negatively on the relaxivity,27 however, this does not seem to be a 
significant factor in the performance of the chelate design reported here. 
 
 
Figure 2. NMRD relaxivity profiles of 6 at 25 and 37 °C and Dotarem® under the same 
conditions. 
 
 The design of the chelator used to complex the gadolinium ion in 6 and 7 is intentionally 
closely based on that of Dotarem®, one of the leading clinically-approved contrast agents. The 
stability of the chelate towards loss of gadolinium ions (and hence its toxicity) was therefore 
expected to be comparable to the contrast agents used in the clinic. This was however probed 
by adding Zn2+ ions to 6 and monitoring the relaxivity values obtained (Supporting 
Information), as described by standard literature protocols.28 This revealed no change in the 
relaxivity even after 100 hours of exposure to 10 eq ZnCl2 at 37 °C. Like Dotarem
®, 
fluorescence lifetime measurements for the europium analogue (8) of compound 6 revealed the 
expected hydration value of q = 1 for the octadentate chelate (Supporting Information). The 
assessment of the gadolinium surface unit was continued in cytotoxicity studies. MTT assays 
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concentrations of 250 µM (Supporting Information), which are even higher than those used 
clinically. 
 
 In addition to their stability under a range of physiological conditions, a great advantage 
of using gold nanoparticles is the ability to combine multiple groups on the surface.29 Unlike 
other platforms, such as molecular systems or liposomes, new combinations of 
imaging/targeting/therapeutic units can be incorporated into assemblies of sizes 2-200 nm 
without fundamental changes to the design. Variables explored in this work include 
combinations of imaging unit (MRI and optical) and targeting alongside features to enhance 
biocompatibility/stealth. The overall aim was to design components which can be assembled 
in a straightforward manner to achieve a nanostructure with the appropriate functionality to 
target and image specific cell types (such as cancer cells). 
 
Targeting groups (aptamers, antibodies etc.) can be chosen to recognise specific molecules 
on the cellular surface which act as early reporters of a given pathology. In a nanoparticle 
system such as the ones described here, the successful recognition of a receptor by a targeting 
group on the NP surface would lead to a high concentration of Gd chelates being present, 
compensating for the very low concentration of such receptors (e.g., overexpressed membrane 
receptors) and the relatively low innate sensitivity of Gd(III) contrast agents.30 
 
As a proof of concept, folic acid was chosen to be added to the assembly to investigate 
uptake in HeLa cancer cells, which overexpress folate receptors on their surface.31 This paves 
the way for more sophisticated and selective targeting units to be introduced in future studies, 
such as DNA/RNA aptamers and antibodies. In the case of tumours, the presence of active 
targeting groups would add to the passive targeting (EPR effect) already established for GNPs. 
This potential for conjugation of different thiol-based commercially-available targeting 
moieties, tailored to recognise specific proteins or disease sites, demonstrates the versatility of 
the proposed nanoparticles and their potential use as imaging platforms. The recognition 
moiety can be chosen based on the specific target and its intra- or extracellular location. 
 
Folic acid (FA) is known to provide additional targeting of nanoparticles beyond the 
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cells.7 A thiol-terminated derivative, FA-SH (9), shown in Scheme 3, was prepared using a 




Scheme 3. Synthesis of a targeting surface unit, FA-SH (9), derived from folic acid.32a 
 
Two further surface units, PEG-SH and thioglucose were used to enhance the functionality 
of the surface architecture. Poly(ethylene)glycol (PEG) units are well established units used to 
enhance biocompatibility, while thioglucose has been suggested to perform a targeting function 
(due to the higher consumption of glucose by tumours)33 as well as conferring water 
solubility.34 
 Gold nanoparticles can be imaged using their interaction with light (fluorescence) and 
this will allow their location and uptake to be visualised in cells. As this fluorescence is weak 
(quantum yields ~0.3%), a thiol-terminated boron-dipyrromethene (BODIPY-SH) fluorophore 
(12, Supporting Information), similar to the type used extensively in biological imaging,35 was 
also attached to the surface of the nanostructures to study their uptake. 
 
Early work in the area30,36 employed thiol precursors to attach Gd chelates to the surface 
of gold nanoparticles (GNPs),37 however there is evidence to indicate loss of thiolates from the 
GNP surface occurs to a substantial degree.21,38 This led us to explore a more robust attachment 
for the Gd unit, resulting in the design of compound 7. The dithiocarbamate unit combines 
superior strength of attachment (compared to thiol(ate)s)20,21,38-40 with limited rotational 
freedom to maximise the relaxivity ‘boost’ obtained on immobilising the Gd chelate on the 
nanoparticle. In addition, its similarity to a clinically-approved design (Dotarem®), enhances 
the likelihood of showing similar biological properties. 
 
A general protocol for the synthesis of gold nanoparticles (Scheme 4) was formulated 
based on the Brust-Schiffrin method.41 All glassware used for the synthesis of GNPs was 
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solution of tetrachloroauric acid was prepared and solutions of the various sulfur-based ligands 
(7, PEG-SH, thioglucose, FA-SH (9), BODIPY-SH (12)) were then introduced in the desired 
quantities and ratios (0.01 - 1 eq. relative to Au). Ultrapure water was used to dissolve PEG-
SH and thioglucose, DMSO for BODIPY-SH (12), and a 1:1 mixture of ultrapure water and 
DMSO for FA-SH (9) and a 1:1 mixture of methanol and acetonitrile for 7. The mixture was 
then cooled to 4 °C and a fresh solution of sodium borohydride in ultrapure water added 
dropwise to reduce the Au(III) precursor to Au(0). The mixture was stirred at 10 °C for 3 hours, 
after which the nanoparticles were then centrifuged at 5300 rpm for 45 minutes. The 
supernatant was removed and the nanoparticles were repeatedly rinsed with ultrapure water a 
minimum of 3 times, until the filtrate failed to show the presence of the unbound Gd chelate 
(7), as determined by measurement of its relaxivity. The nanoparticles were then resuspended 
in ultrapure water and stored in this form. Indeed, even after 6 months, the functionalised 
nanoparticles could be re-suspended and their relaxivity measured. This revealed no changes 
in their performance and indicate their long-term stability.  
 
 
Scheme 4. Synthesis of GNPs with 7 and other surface units (R1-SH, R2-SH, R3-SH). 
 
A total of 7 types of functionalised GNPs were prepared with different surface units 
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Figure 3. Nanoparticle surface functionalization with proportions of surface units used. 
 
This approach represents a rapid and straightforward route to the preparation of 
multifunctionalised gold nanoparticles in which the greater strength of attachment (compared 
to thiolates) of the DTC unit (7) ensures the retention of the Gd contrast agent. Transmission 
electron microscopy (TEM) was used to determine the diameter and size distribution of the 
nanoparticles (Figure 4). A reasonably narrow size distribution was found with the 
nanoparticles being around 4.4 nm in diameter (ranging from 4.18 – 4.55 nm). Dynamic light 
scattering (DLS) measurements for the PEGylated NPs suggested that the hydrodynamic radius 
increases from 4-5 nm to approximately 20 nm due to the PEGylated thiolate surface units 
(PEG-2000). Dispersive X-ray spectroscopy (EDS) was used to confirm the presence of Gd 
and Au in the assemblies (Figure 4). The ratio of Gd and Au was more accurately determined 
by inductively-coupled plasma optical emission spectroscopy (ICP-OES) and allowed the 
number of Gd chelates per GNP to be calculated and this was used for relaxivity measurements. 
These data were compared to thermogravimetric analysis (TGA) for NP1 (bearing just 7 on the 
surface) and found to be in good agreement. For NP1 it was calculated42 from TEM and ICP-
OES data that there are approximately 120 Gd chelates per nanoparticle. As no other surface 
units are present, this can be assumed to be close to the maximum possible loading of Gd units 
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Figure 4. TEM (left) and EDS (right) data for NP1. 
 
It is well established that the addition of PEG-SH units improves the solubility of GNPs 
in biological media, enhances biocompatibility and performs a ‘stealth’ function,43 which 
would be important in any clinical application as it prevents removal by the body’s defences 
(e.g. macrophages). Using an adapted procedure (Scheme 4) to that employed for the synthesis 
of NP1, nanoparticles (NP2 and NP3) with mixed surface units were prepared, using different 
ratios of PEG-SH and the Gd chelate (7). Nanoparticles functionalised with more than two 
surface units (NP4 - NP7) were synthesised using only 0.05 mole equivalents of PEG as NP2 
was visibly less stable than NP3 after 3 weeks of storage. 
 In addition to 7, thioglucose was also added in equimolar amounts to PEG-SH to 
generate NP4, which resulted in a triply functionalised surface. Despite the overlapping bands 
from the various surface units, which have many functional groups in common, analysis of the 
infrared spectroscopic data indicated the presence of an absorption band at around 1237 cm−1, 
which was assigned to thioglucose. 
Two further assemblies (NP5 and NP6) were functionalised with the thiol-modified 
derivative of folic acid (FA-SH, 9), differing only in the Gd : FA-SH ratio (Figure 3). NP6 was 
prepared in order to demonstrate that four separate surface units (Gd, PEG, TG and FA) could 
be combined on the surface of the nanoparticle without a significant compromise in the 
relaxivity performance. The final nanoparticle assembly (NP7) included a BODIPY (12) unit 
to aid tracking of the assembly using fluorescence (vide infra). Thermogravimetric analysis 
(TGA) performed on NP2 – NP7 indicated that between 20 and 34% of the mass of the 
nanoparticles was due to the surface units, however, due to the sensitivity of the technique, 














Chemistry - A European Journal
This article is protected by copyright. All rights reserved.
Electronic spectroscopy (UV-vis) was used to observe the surface plasmon resonance 
(SPR) band for each assembly (at approximately 550 nm). For each nanoparticle, zetapotential 
measurements were carried out to provide information on the stability of the nanoparticles 
towards agglomeration. These ranged between −30.4 and −35.8 mV (Supporting Information), 
indicating good stability and resistance to agglomeration. 
 
 The nanoparticles were also found to be stable for at least 24 hours across a range of 
pH values between 4 – 10 (HEPES buffer solution). The stability in the presence of NaCl was 
tested in water and monitored by UV-vis spectroscopy, showing no tendency to precipitate 
over a period of 24 hours. The same technique was used to analyse their behaviour in biological 
media, which revealed no changes to the data. See Supporting Information for further details. 
 
 The relaxivity of the various nanoparticle assemblies was measured at 37 °C in water 
and NMRD profiles were determined. It is known that the immobilisation of gadolinium 
chelates on a polymer or nanoparticle surface often results in an enhancement of the 
relaxivity.11,45 This is due to slow tumbling and a reduction in the rotational freedom 
experienced by each individual Gd chelate. However, a particularly pronounced enhancement 
was observed for the materials prepared in this study (up to five times higher relaxivity per 
Gd). This can partly be attributed to the particularly rigid design of 7, which has multiple bond 
character in the C-N bonds of both the dithiocarbamate and amide linkages. A representative 
NMRD profile is shown below (Figure 5). Previous designs based on thiol-modified chelates 
allow rotation about the axis of the tether30,34,36,37,44 or can lead to the formation of disulfide 
linkages, creating flexible chains of Gd chelates anchored at only a few points to the surface.36a 
For example, many reports use long PEG-thiolate chains terminated in a Gd unit, which retain 
their internal flexibility and this restricts the enhancement observed. (Scheme S2-1 in ESI).44 
These effects potentially reduce the benefit of immobilisation on the nanoparticle surface and 
are sometimes overlooked due to the tendency to quote relaxivity per nanoparticle rather than 
per Gd. 
 
 Nanoparticles with only Gd surface units (NP1) show good water solubility and were 
found to exhibit an 8-fold enhancement over the unattached surface unit 6 (from 4.0 mM-1 s-1 
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Figure 5. NMRD profiles of NP1 and 6. 
 
The relaxivity performance of NP1 exemplifies the effect of immobilising the Gd 
chelates on the nanoparticles. These nanoparticle-bound chelates displayed a dramatic 
relaxivity enhancement (7.6 times greater for NP1) compared to that of non-immobilised 6, as 
can be seen from the NMRD profiles shown in Figure 5 and Table 1. For NP1, relaxivities of 
r1 = 34.3 mM
-1 s-1 per Gd and r1 = 4203 mM
-1 s-1 per nanoparticle were achieved (at 10 MHz, 
37 °C). This represents the highest relaxivity enhancement per Gd ion yet reported for small 
spherical gold nanoparticles that could potentially be used in a clinical setting. A slightly higher 
value (r1 ~ 40 mM
-1 s-1 at 10 MHz, 37 °C) was reported by Helm and co-workers36b for gold 
nanoparticles with a surface unit based on a heptadentate chelate with a hydration number of 
two. The authors suggest that this design would be suitable for pre-clinical but not clinical 
imaging (on account of nephrogenic systemic fibrosis concerns), due to the lower stability of 
the chelate. This performance of NP1 can be attributed to the internal rigidity of the Gd surface 
unit provided by the multiple bond character present at either end of the dithiocarbamate linker 
(in both DTC and amide units). The lack of rigidity within the Gd surface unit and tether has 
been identified45 as the main factor limiting the relaxivity enhancement in gold nanoparticles 
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 The relaxivity of simple, monometallic Gd-based contrast agents is severely affected 
by the short rotational correlation time. An increase in temperature causes more rapid tumbling 
and so decreases r1 values still further despite the higher water exchange rate at elevated 
temperatures. In current designs based on Gd chelates attached to nanoparticles,13,36,37,44 slower 
tumbling is achieved but internal rotation (e.g. about the tether) limits the enhancement through 
this effect. Due to the rigidity introduced into our system by the dithiocarbamate, an increase 
in temperature has little impact on the rotation of the Gd surface unit (7), while still allowing 
the beneficial effects of a higher water exchange rate. This can be seen in Figure 6, which plots 
the relaxation rate (R1) at temperatures between 30 – 70 °C over the value at 30 °C (at 7 MHz) 
for monometallic 6 and NP1. This reveals the expected decrease in values for 6, whereas the 
corresponding experiments for NP1 lead to an increase in relaxation rate. 
 
 
Figure 6. Plot of the ratio of relaxation rate (R1) at temperatures between 30 – 70 °C relative 
to the value at 30 °C (at 7 MHz) for monometallic 6 and NP1. 
 
The GNPs functionalised with PEG-SH units (NP2 and NP3) showed a slightly reduced 
relaxivity per Gd compared to NP1 possibly due to crowding of the Gd chelates by the PEG 
units, reducing their exposure to the bulk water (Table 1). 
Relaxivity data were also recorded for NP2 – NP7 in order to explain the effect of 
adding further groups to the GNP surface. Increasing the complexity of the surface architecture 
does have some impact on the relaxivity per Gd centre (Figure 7 and Figure S8-8 in the 
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compound 6 is still substantial. The reduction in relaxivity per Gd observed could be due to a 
number of factors. The presence of the substantially longer and more flexible PEG units could 
hinder water coordination, exchange and outer sphere relaxation effects, while the lower 
density of Gd chelates would reduce the likelihood of enhanced relaxivity through the 
cooperative action of neighbouring Gd chelates. Interestingly, the presence of thioglucose 
seems to enhance the relaxivity, as has been noted previously.34,46 This could be due to the 
small size of the thioglucose units relieving the crowding of the Gd chelates caused by the 




Figure 7. NMRD profiles (per Gd) for the nanoparticles at 37 °C. 
 
The use of additional surface units for other functions (biocompatibility, targeting, 
therapy etc.) should lead to an overall reduction in relaxivity per nanoparticle due to fewer Gd 
chelates being present on the nanoparticle surface. This is evident in Figure 8 and Table 1, with 
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Table 1. Summary of the relaxivity values (mM-1 s-1) for the various GNPs measured at 25 and 





25 °C 37 °C 








NP1 122 31.49 3855 34.34 4203 
NP3 89 20.63 1830 27.27 2423 
NP4 75 34.94 2605 33.19 2473 
NP5 86 26.13 2256 28.06 2423 
NP6 82 22.39 1831 25.94 2120 
6 - 5.34 - 4.54 - 
Dotarem® - 4.89 - 3.94 - 
 
 
The overall r1 value per nanoparticle (TEM: around 4.4 nm in diameter) decreases from 
4203 mM-1 s-1 for NP1 (Gd only, at 10 MHz, 37 °C) to 2120 mM-1 s-1 for NP6 (at 10 MHz, 37 
°C) due to the lower loading of Gd chelates on the surface. However, the localised impact of 
this large relaxation effect will still be substantial and should lead to a great contrast 
enhancement compared to the diffuse and non-localised effect of monometallic species such as 
Dotarem®. Indeed, if the targeting moieties on the nanoparticle were to bring such a high 
payload of Gd into the vicinity of a receptor expressed by a tumour, the contrast enhancement 
observed would be much greater as a result of this single receptor compared to a targeting unit 
linked to one or only a few Gd centres. In addition to their high localised relaxivity, the small 
sizes of the nanoparticles described here allow them to penetrate membranes more easily than 
larger nanostructures. However, if larger GNPs are required, the approach described here can 
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Figure 8. NMRD profiles for three representative nanoparticles in the study (NP1, NP4, NP6) 
as measured per nanoparticle at 37 °C.  
 
The GNPs were tested for their effect on various cell lines using MTT assays. They 
were found not to be cytotoxic towards the cell lines tested (HeLa, MCF-7) at concentrations 
up to 250 M (Supporting Information). 
Measurement of GNP uptake (HeLa and MCF-7) was determined after incubation for 
24 hours with the differently functionalised GNPs. HeLa and MCF-7 cell lines were chosen 
due to their differing expression of the folate receptor (higher in HeLa).47 
 
Figure 9. ICP-OES experiments measuring the uptake of gold (in pg/cell) in HeLa (left) and 
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 The data in Figure 9 show that the more highly functionalised nanoparticles display 
greater uptake after 6 and 24 hours than the materials with only Gd surface units (NP1) or Gd 
and PEG units (NP3). HeLa cells express the folate receptor to a greater extent than MCF-7 
cells47 and this could explain the enhanced uptake of NP6 (particularly after 6h), which is the 
only assembly functionalised with folic acid. However, it is likely that the uptake observed is 
not solely due to the presence of the folic acid group as NP4 (bearing thioglucose but not folic 
acid) also shows increased uptake. Further studies will be conducted to investigate the uptake 
mechanism in more detail, including using unbound folic acid as part of a competition study. 
In future research, it is likely to be beneficial to exchange folic acid for a nucleic acid aptamer, 
which is capable of binding to its target with high affinity and specificity.48 
 
Widefield microscopy (FILM, Imperial College) was used to show (in HeLa cells), that 
the GNPs enter the cells but apparently not the nucleus (Figure 10). This was determined using 
BODIPY-functionalised nanoparticles. When characterised, these nanoparticles showed 
quenching of the BODIPY fluorescence (heavy atom effect) by the gold nanoparticle due to 
the short length of the tether. This is in accordance with previous studies on the effect of tether 
length on quenching.49 However the fluorescence is observed after one hour of incubation in 
the microscopy images (predominantly inside the cells, which supports the ICP-OES data for 
cell uptake), suggesting that the BODIPY unit (12) has detached from the nanoparticle surface, 
leading to revival of the fluorescence. This can be taken as further evidence for the loss of some 
of the thiolate units from the surface under biological conditions,39e reinforcing the need for 
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Figure 10. Widefield images (fluorescence above and brightfield below) showing 
fluorescence due to release of the BODIPY-thiolate surface unit (12) from NP7 ([Au] = 200 
M) after a) 1 h incubation, b) 24 h incubation, c) control with no GNP and d) a close up of 
cells after 24 h incubation. Excitation at 450 nm. 
 
 The T1-weighted MR images of the nanoparticles shown in Figure 11 were measured 
on a clinical scanner at 63.87 MHz (1.5 T) and compared to Dotarem®. This reveals that for 
the same concentration of Gd3+ ions (0.02 mM), significantly greater contrast can be achieved 
per Gd3+ unit in NP1 (r1 = 22 ± 2 mM
-1s-1) and NP6 (r1 = 14 ± 1 mM
-1s-1) compared to 
Dotarem® (r1 = 4.5 ± 0.3 mM
−1 s−1). As expected, and in agreement with previous reports on 
other gold nanoparticle-based contrast agents,12 there is a reduction of relaxivity at the higher 
frequency used by clinical scanners compared to at 10 MHz (NP1, r1 = 31.49 mM
-1s-1; NP6, r1 
= 22.39 mM-1s-1). 
 
 
Figure 11. T1-weighted MR images of Dotarem®, NP1 and NP6 at 25 °C at 63.87 MHz 
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 The approximately 3.5x and 4.8x increase in relaxivity per Gd of both NP1 and NP6, 
respectively, at clinical field compared to Dotarem®, combined with their biocompatibility and 





Many strategies have been employed to enhance the relaxivity offered by trivalent gadolinium 
chelates for use in MRI11,45 and one of the most successful is their immobilisation on the surface 
of gold nanoparticles. Alongside the advantages, such as slow tumbling and passive targeting, 
drawbacks associated with thiolate tethers need to be avoided, such as the formation of 
undesirable disulfide bonds and the internal flexibility (and rotation about) the tether. As a 
solution to these limitations, this contribution describes the multigram synthesis of a new 
octadentate gadolinium chelate (7) based on the clinically-approved DOTA scaffold (q = 1) 
with a rigid tether. This piperazine-based unit prevents rotation due to the multiple bond 
character in the amide moiety at one end and through the robust, dithiocarbamate anchor at the 
other. Furthermore, this attachment at two points on the gold surface through the two sulfur 
atoms of the dithiocarbamate avoids the rotation permitted by the single Au-S interaction of 
thiolate surface units. This is the first time a dithiocarbamate has been used to generate 
nanoparticles bearing Gd chelates (with q = 1) that are suitable for use in MRI, following our 
previous report of a dithiocarbamate-functionalised hexadentate chelate (q = 3).15 A relaxivity 
enhancement per Gd of up to 8 times is observed compared to unattached 6 (at 10 MHz) and 
the overall assembly displays r1 values of around 4200 mM
-1 s-1 per nanoparticle. Under clinical 
conditions (1.5 T, 63.87 MHz), enhancements per Gd of 3.5 - 4.8x compared to Dotarem® are 
observed. In contrast to monometallic (e.g., Dotarem®) or Gd chelates immobilised on 
nanoparticles or polymers where internal rotation is possible, an increase in temperature (as 
observed between 25 and 37 °C) results in an enhancement of the measured r1 values and this 
is attributed to the combination of the rigidity in our system and the improved water exchange 
at elevated temperatures. Given that pathologies, such as tumours, typically express only a few 
receptors, the targeting of these receptors with a large payload of Gd chelates will help locate 
diseased tissue through a vastly improved MRI signal. The use of the dithiocarbamate surface 
unit to attach the most valuable component (MRI modality) of the surface architecture both 
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be used in an orthogonal approach to creating mixed surfaces. In our work, this has been 
exploited to provide a straightforward and versatile ‘one-pot’ synthetic approach to generate 
multifunctional nanoparticles with up to four other surface units to add biocompatibility (PEG-
SH), targeting (FA-SH), uptake (thioglucose) and optical imaging (BODIPY-SH) properties. 
As well as being non-toxic, the resulting nanoparticles show very good stability (Supporting 
Information) when tested under different pH conditions, high salt concentrations and for 
potential transmetallation (with Zn2+ ions). In addition to the passive targeting attributed to 
gold nanoparticles (EPR effect), the inclusion of a unit capable of selectively targeting 
overexpressed receptors in cancer cells illustrates the potential of these assemblies. The small 
size of the nanoparticles is also suited to relatively short circulation times and good clearance 
properties. 
Our current investigations focus on combining the enhanced magnetic resonance 
imaging properties of these materials with therapeutic options. Potentially, this will allow 
functionalised nanoparticles to be used to both evaluate disease progression and deliver 
therapeutic interventions. The work described here has provided a new methodology for 
functionalising nanoparticles using highly stable Gd chelates with a dithiocarbamate tether. 





The synthesis and subsequent characterization of the functionalised nanoparticles are described 
in the ESI along with details of cytotoxicity and cell uptake studies. 
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